Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
94 hedge funds and large institutions have $187M invested in Eiger BioPharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 17 reducing their positions, and 17 closing their positions.
176% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 17
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
54% more capital invested
Capital invested by funds: $122M → $187M (+$65.5M)
1% more funds holding
Funds holding: 93 → 94 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.01M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.87M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2.59M |
| 4 |
Goldman Sachs
New York
|
+$2.31M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$2.86M |
| 2 |
Renaissance Technologies
New York
|
-$1.84M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.36M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.13M |
| 5 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$590K |
EIGR Hedge Fund Activity: Q2 2020 in Review
94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2020, worth a combined $187M — up 54% from $122M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new EIGR positions and 17 closed out — a net gain of 1 holder — while 47 added to existing stakes and 17 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $3.01M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $2.86M sold.
- 94 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2020, up from 93 in Q1 2020.
- Funds reported $187M of Eiger BioPharmaceuticals, Inc. stock for Q2 2020, up 54% quarter-over-quarter.
- 18 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2020 and 17 closed out, a net change of +1 holder.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2020 was Adage Capital Partners, an estimated $3.01M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2020 was J. Goldman & Co, an estimated $2.86M sold.
Based on aggregated 13F filings for Q2 2020.